Abstract Library

#2927 Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies

Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Barriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A,

Keywords: goblet cell adenocarcinomas, chemotherapy, anti-egfr,

#1773 Clinical Outcomes of Systemic Chemotherapy in Patients with High Grade Neuroendocrine Carcinoma of Biliary Tract

Introduction: : Neuroendocarine tumor of biliary tract is very rare and clinical outcomes of advanced neuroendocrine tumors of biliary tract has not been well demonstrated.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Yoo C, Lee K, Kim K, Chang H, Ryoo B,

Keywords: biliary tract, high grade, neuroendocrine carcinoma,

#1590 Treatment of Metastatic Pancreatic Neuroendocrine Tumors: Relevance of ENETS 2016 Guidelines

Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki67<10%, low tumor burden, no symptoms, and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group-3, symptomatic patients or with Ki67>10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Foulfoin M

Authors: Foulfoin F, Graillot E, Adham M, Rousset P, Forestier J,

Keywords: pancreas, metastasis,

#1504 Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs

Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Reidy-Lagunes D

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Mirakhur B, Massien C,

Keywords: Lung NETs, lanreotide,

#1261 Emergency Therapy for Liver Metastases from Advanced VIPoma: Surgery or Transarterial Chemoembolization

Introduction: VIPoma is a rare neuroendocrine tumor (NET) with a high potential to develop hepatic metastases and poor prognosis. The primitive tumor is non-symptomatic and usually localized within the pancreas. Liver metastasis drove the prognosis and induced profuse watery diarrhea or renal failure.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Coriat R

Authors: Dréanic J, Lepère C, Mostafa E, Gouya H, Rougier P,

Keywords: vipoma, hepatectomy, Trans Arterial Chemo Embolization (TACE), neuroendocrine tumors (NET), vasoactive intestinal peptide (VIP), systemic chemotherapy,